ILK is constitutively active in AML [66] and favors cell growth and survival by the activation of AKT and inhibition of glycogen synthase kinase-3-β (GSK3B), therefore stabilizing β-catenin [67,68], the transcriptional co-activator in the canonical Wnt pathway [69]. The gene discussed is ILK; the disease is acute myeloid leukemia.